Ulrich Alfons Müller (U A Müller)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

Journal of clinical medicine

Acta diabetologica

Diabetic medicine : a journal of the British Diabetic Association

Dr. Kielstein Ambulante Medizinische Versorgung GmbH

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Dr. Kielstein Ambulante Medizinische Versorgung GmbH Aug 13 2020

Germany

Endocrinologist :: Practise for Diabetology and Endocrinology

Universitätsklinikum Jena Apr 01 2019 - Aug 12 2020

Germany

Endocrinologist :: Zentrum für ambulante Medizin, Praxis für Endokrinologie und Diabetologie

Universitätsklinikum Jena Aug 01 1982 - Dec 31 2019

Germany

Haed of Dpt. Endocrinology and Metabolic Diseases :: Internal Medicine, Endocrinology and Metabolic Diseases

Publications

Dilvin Semo, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, Johannes Waltenberger
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of clinical medicine 12 (4) (2023)
Dilvin Semo, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, Johannes Waltenberger
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of clinical medicine 12 (4) (2023)
Dilvin Semo, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, Johannes Waltenberger
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of clinical medicine 12 (4) (2023)
Dilvin Semo, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, Johannes Waltenberger
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of clinical medicine 12 (4) (2023)
Maximilian Hopf, Christof Kloos, Gunter Wolf, Ulrich Alfons Müller, Nicolle Müller
Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2. Journal of clinical medicine 10 (4) (2021)
A M S Spraul, A M Schönbach, Nicolle Müller, Ulrich Alfons Müller, A Koller, M Spraul
Long-term outcome of persons with diabetic and non-diabetic neuro-osteoarthropathy after foot correction using external fixation. Diabetic medicine : a journal of the British Diabetic Association 38 (4) (2020)
Christoph Werner, Nicolle Müller, Ulrich Alfons Müller
Agonistic autoantibodies against B2-adrenergic receptors correlating with macrovascular disease in longstanding diabetes type 2. Acta diabetologica 56 (6) (2019)
Christoph Werner, Nicolle Müller, Ulrich Alfons Müller
Agonistic autoantibodies against adrenergic receptors correlating with antihypertensive therapy in long-standing diabetes type 2. Acta diabetologica 55 (3) (2018)

Ulrich Alfons Müller.css-eqlu8i{font-size:small;padding-left:4px;} (U A Müller)

Publication Activity (10 Years)

Top Topics

Top Venues

Ulrich Alfons Müller (U A Müller)